Abstract

Osteosarcoma (OS) is the most common human primary skeletal malignancy. However, current treatment strategies rely heavily on surgical intervention and there are no curative systemic therapies available for the treatment of OS. Deregulated signalling through the Fibroblast Growth Factor Receptor (FGFR) family has recently been implicated in both the pathogenesis as well as skeletal metastasis of both breast and prostate cancer. However, the role and therapeutic potential of FGF signalling in OS is not well established.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.